Contera Pharma A/S
Public limited companyCVR 33062214HørsholmActive
Contera Pharma A/S is a public limited company, based in Hørsholm, active in research and experimental development on natural sciences and engineering, founded in 2010. The company made a loss in both 2024 and 2025, most recently DKK 4.8m. With 21 employees, the company is about 4 times larger than the industry median. Equity grew to DKK 79.5m in 2025.
Key figures · financial year 2025
Gross profitDKK 20.6m+138.1% vs. 2024
Net profit−DKK 4.8m+93.1% vs. 2024
EquityDKK 79.5m+46.1% vs. 2024
Employees21latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss got smaller: from DKK 69.2m to DKK 4.8m (2024 → 2025).
- Equity rose 46% (2024 → 2025), to DKK 79.5m.
Employees
- 6 more employees than a year earlier: 21 (08/2026) against 15 (08/2025).
Management and owners, last 24 months
- New in management: Jee Hun Kim (board member, 10/04/2026), Jae Young Lee (chair of the board, 25/08/2026) and Mahmoud Mahmoudian (board member, 01/12/2024) (+3).
- Stepped down: Jae Young Lee (board member, 24/08/2026), WooHyun Lee (chair of the board, 10/04/2026) and Mahmoud Mahmoudian (board member, 25/08/2026) (+3).
Registrations, last 24 months
- 14/07/2026: Share capital changed from 2,708,158 DKK to 4,198,724 DKK
- 15/10/2025: Share capital changed from 1,885,113 DKK to 2,708,158 DKK
- 15/04/2025: Share capital changed from 1,403,186 DKK to 1,885,113 DKK
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | −9,725 | −24,154 | −44,832 | −58,994 | −54,084 | 20,632 | +138.1% |
| Operating profit (EBIT) | −13,496 | −36,392 | −62,084 | −78,260 | −75,626 | −5,984 | +92.1% |
| Profit before tax | −13,835 | −36,581 | −62,368 | −76,820 | −74,714 | −6,063 | +91.9% |
| Net profit | −12,259 | −31,519 | −56,868 | −71,320 | −69,214 | −4,784 | +93.1% |
| Total assets | 201,326 | 167,213 | 115,743 | 92,369 | 63,610 | 97,551 | +53.4% |
| Equity | 194,961 | 163,442 | 106,574 | 86,298 | 54,388 | 79,472 | +46.1% |
| Liabilities | 6,365 | 3,771 | 9,169 | 6,071 | 9,222 | 18,079 | +96.1% |
| Cash and cash equivalents | 196,219 | 159,887 | 88,513 | 67,128 | 41,474 | 84,445 | +103.6% |
| Average number of employees | 4 | 13 | 14 | 17 | 19 | 14 | −26.3% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 6 years in a row
Net result has been negative in 2020–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
Fewer employees
The number of employees fell 26% from 19 in 2024 to 14 in 2025.
How is this calculated?
The number of employees according to the annual report has fallen by at least 25%, and was at least 10 the year before.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 15/04/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 19/05/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 14/05/2024 | The company | PDFXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 24/04/2023 | The company | PDFXBRL |
| 2021 | 01/01/2021 – 31/12/2021 | 16/06/2022 | The company | PDFXBRL |
| 2020 | 01/01/2020 – 31/12/2020 | 26/03/2021 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Gross profitDKK 20.6mNo. 57 of 421
Better than 87% of the companies in the industry
EquityDKK 79.5mNo. 46 of 431
Better than 90% of the companies in the industry
Number of employees21No. 115 of 431
Better than 73% of the companies in the industry
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with 20–49 employees9,922 companies in the comparison | No. 2,707of 9,892 Better than 73% | No. 450of 9,922 Better than 95% |
| Same industry and 20–49 employees64 companies in the comparison | No. 16of 62 Better than 75% | No. 17of 64 Better than 75% |
| Companies that are between 15 and 29 years old24,910 companies in the comparison | No. 3,291of 24,791 Better than 87% | No. 1,635of 24,909 Better than 93% |
| All companies of type A/S18,025 companies in the comparison | No. 5,790of 17,786 Better than 67% | No. 2,661of 18,024 Better than 85% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineeringGross profit
- Contera Pharma A/SDKK 20.6m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
Net profit
- Contera Pharma A/S−DKK 4.8m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
Equity
- Contera Pharma A/SDKK 79.5m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
Employees
- Contera Pharma A/S21
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
- Bukwang Pharmaceutical Co., Ltd90%
Contera Pharma A/S
Management
5 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Thomas Nikolaj Sager | CEO | 01/12/2020 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Thomas Nikolaj Sager | Board member | 01/07/2022 |
| Paul Ejnar Gremaud Kristjansen | Board member | 01/03/2024 |
| Jee Hun Kim | Board member | 10/04/2026 |
| Jae Young Lee | Chair of the board | 25/08/2026 |
- Founders
- Concit Pharma Holding ApS
Former management (23)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Mikael Søndergaard Thomsen | Director | 09/07/2010 | 30/06/2018 |
| John Bondo Hansen | Board member | 06/08/2010 | 19/11/2013 |
| John Bondo Hansen | CEO | 06/08/2010 | 01/12/2020 |
| Mikael Søndergaard Thomsen | Board member | 06/08/2010 | 18/04/2012 |
| Frank Knudsen | Board member | 07/01/2011 | 18/04/2012 |
| Bobby G Soni | Board member | 26/04/2011 | 24/11/2014 |
| Carsten Schou | Board member | 18/04/2012 | 24/11/2014 |
| Gunnar Magnus Severus Modee Persson | Board member | 18/04/2012 | 24/11/2014 |
| Else Sissel Vorstrup | Board member | 19/11/2013 | 24/11/2014 |
| Joseph Donald deBethizy | Chair of the board | 19/11/2013 | 24/11/2014 |
| Sang Hoon Kim | Board member | 24/11/2014 | 13/11/2020 |
| Hee Won Yoo | Chair of the board | 24/11/2014 | 17/11/2023 |
| Jung Yoon Um | Board member | 22/02/2019 | 30/04/2021 |
| Eun Ju Kim | Board member | 13/11/2020 | 28/03/2022 |
| Sun Ho Kim | Board member | 30/04/2021 | 09/02/2023 |
| Sung Joon Kim | Board member | 28/03/2022 | 03/07/2023 |
| WooHyun Lee | Board member | 01/07/2022 | 16/11/2023 |
| Jae Young Lee | Board member | 03/07/2023 | 24/08/2026 |
| WooHyun Lee | Chair of the board | 17/11/2023 | 10/04/2026 |
| Mahmoud Mahmoudian | Board member | 01/12/2024 | 25/08/2026 |
| Soo Yeon Park | Board member | 01/12/2024 | 15/04/2025 |
| Mi Chung Ahn | Board member | 15/04/2025 | 09/04/2026 |
| Mi Chung Ahn | Chair of the board | 10/04/2026 | 25/08/2026 |
Signing rule: Selskabet tegnes af bestyrelsesformanden i forening med selskabets administrerende direktør.
Address and production units
1 active production unitsVenlighedsvej 4
2970 Hørsholm
Rudersdal Municipality · Postcode 2970
Other companies at the address (2)
- Presto Engineering Denmark ApSResearch and experimental development on natural sciences and engineering
- Dralle A/SComputer programming activities
| Production unit | Address | Employees | P number |
|---|---|---|---|
| CONTERA PHARMA A/S | Venlighedsvej 4, 2970 Hørsholm | 21 | 1016181214 |
Purpose
Selskabets formål er at udvikle nye lægemidler og dermed beslægtet virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
89 registered events02015
02016
02017
42018
42019
92020
32021
62022
82023
92024
62025
102026
202610 changesmanagement 8 · capital 1 · accounts 1
- ManagementJae Young Lee appointed chair of the board
- ManagementMi Chung Ahn stepped down as chair of the board
- ManagementMahmoud Mahmoudian stepped down as board member
- ManagementJae Young Lee stepped down as board member
- CapitalShare capital changed from 2,708,158 DKK to 4,198,724 DKK
- AccountsAnnual report for 2025 published
- ManagementJee Hun Kim appointed board member
- ManagementMi Chung Ahn appointed chair of the board
- ManagementWooHyun Lee stepped down as chair of the board
- ManagementMi Chung Ahn stepped down as board member
20256 changescapital 2 · accounts 1 · management 2 · industry 1
- CapitalShare capital changed from 1,885,113 DKK to 2,708,158 DKK
- AccountsAnnual report for 2024 published
- CapitalShare capital changed from 1,403,186 DKK to 1,885,113 DKK
- ManagementMi Chung Ahn appointed board member
- ManagementSoo Yeon Park stepped down as board member
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20249 changesmanagement 3 · capital 2 · accounts 1 · ownership 3
- ManagementMahmoud Mahmoudian appointed board member
- ManagementSoo Yeon Park appointed board member
- CapitalShare capital changed from 1,066,486 DKK to 1,403,186 DKK
- CapitalShare capital changed from 652,693 DKK to 1,066,486 DKK
- AccountsAnnual report for 2023 published
- OwnershipBukwang Pharmaceutical Co., Ltd registered as owner (90%)
- OwnershipMedici 2020-1 Private Equity Fund is no longer registered as owner
- OwnershipBukwang Pharmaceutical Co., Ltd is no longer registered as owner
- ManagementPaul Ejnar Gremaud Kristjansen appointed board member
20238 changesmanagement 6 · capital 1 · accounts 1
- ManagementWooHyun Lee appointed chair of the board
- ManagementHee Won Yoo stepped down as chair of the board
- ManagementWooHyun Lee stepped down as board member
- CapitalShare capital changed from 621,443 DKK to 652,693 DKK
- ManagementJae Young Lee appointed board member
- ManagementSung Joon Kim stepped down as board member
- AccountsAnnual report for 2022 published
- ManagementSun Ho Kim stepped down as board member
20226 changesaddress 1 · management 4 · accounts 1
- AddressMoved to Venlighedsvej 4, 2970 Hørsholm
- ManagementWooHyun Lee appointed board member
- ManagementThomas Nikolaj Sager appointed board member
- AccountsAnnual report for 2021 published
- ManagementSung Joon Kim appointed board member
- ManagementEun Ju Kim stepped down as board member
20213 changesmanagement 2 · accounts 1
- ManagementSun Ho Kim appointed board member
- ManagementJung Yoon Um stepped down as board member
- AccountsAnnual report for 2020 published
20209 changesaddress 1 · management 4 · capital 1 · ownership 3
- AddressMoved to Agern Alle 24, 2970 Hørsholm
- ManagementThomas Nikolaj Sager appointed ceo
- ManagementJohn Bondo Hansen stepped down as ceo
- ManagementEun Ju Kim appointed board member
- ManagementSang Hoon Kim stepped down as board member
- CapitalShare capital changed from 511,443 DKK to 621,443 DKK
- OwnershipBukwang Pharmaceutical Co., Ltd registered as owner (66.67%)
- OwnershipMedici 2020-1 Private Equity Fund registered as owner (25%)
- OwnershipBukwang Pharmaceutical Co., Ltd is no longer registered as owner
20194 changescapital 2 · name 1 · management 1
- CapitalShare capital changed from 501,443 DKK to 511,443 DKK
- NameName changed from CONTERA PHARMA ApS to CONTERA PHARMA A/S
- CapitalShare capital changed from 374,211 DKK to 501,443 DKK
- ManagementJung Yoon Um appointed board member
20184 changescapital 1 · ownership 2 · management 1
- CapitalShare capital changed from 360,211 DKK to 374,211 DKK
- OwnershipBukwang Pharmaceutical Co., Ltd registered as owner (66.67%)
- OwnershipBukwang Pharmaceutical Co., Ltd is no longer registered as owner
- ManagementMikael Søndergaard Thomsen stepped down as director
201412 changesaddress 2 · management 7 · ownership 1 · capital 2
- AddressMoved to Ole Maaløes Vej 3, 2200 København N
- ManagementHee Won Yoo appointed chair of the board
- ManagementSang Hoon Kim appointed board member
- ManagementJoseph Donald deBethizy stepped down as chair of the board
- ManagementElse Sissel Vorstrup stepped down as board member
- ManagementGunnar Magnus Severus Modee Persson stepped down as board member
- ManagementCarsten Schou stepped down as board member
- ManagementBobby G Soni stepped down as board member
- OwnershipBukwang Pharmaceutical Co., Ltd registered as owner (100%)
- CapitalShare capital changed from 343,792 DKK to 360,211 DKK
- CapitalShare capital changed from 303,066 DKK to 343,792 DKK
- AddressMoved to Kvæsthusgade 5C, 4, 1251 København K
20134 changesname 1 · management 3
- NameName changed from CONCIT PHARMA ApS to CONTERA PHARMA ApS
- ManagementJoseph Donald deBethizy appointed chair of the board
- ManagementElse Sissel Vorstrup appointed board member
- ManagementJohn Bondo Hansen stepped down as board member
20125 changescapital 1 · management 4
- CapitalShare capital changed from 157,514 DKK to 303,066 DKK
- ManagementGunnar Magnus Severus Modee Persson appointed board member
- ManagementCarsten Schou appointed board member
- ManagementFrank Knudsen stepped down as board member
- ManagementMikael Søndergaard Thomsen stepped down as board member
20113 changescapital 1 · management 2
- CapitalShare capital changed from 106,607 DKK to 157,514 DKK
- ManagementBobby G Soni appointed board member
- ManagementFrank Knudsen appointed board member
20106 changescapital 1 · management 4 · founded 1
- CapitalShare capital changed from 80,000 DKK to 106,607 DKK
- ManagementMikael Søndergaard Thomsen appointed board member
- ManagementJohn Bondo Hansen appointed ceo
- ManagementJohn Bondo Hansen appointed board member
- FoundedRegistered as CONCIT PHARMA ApS
- ManagementMikael Søndergaard Thomsen appointed director
Related companies
Same industry in Rudersdal
- Dhi A/S345 employees
- Bioneer A/S82 employees
- Dansk Fundamental Metrologi A/S55 employees
- Glycom A/S51 employees
- Evaxion A/S46 employees
- Presto Engineering Denmark ApS39 employees
Same people in management
- Glycom A/Svia Frank Knudsen
- Saniona A/Svia Joseph Donald deBethizy
- Pentabase A/Svia Frank Knudsen
- Minervax ApSvia Carsten Schou
- Acesion Pharma ApSvia Bobby G Soni
- Carnad A/Svia Frank Knudsen
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.